Company News
Meet Atrandi Biosciences at ASHG 2026 in Montreal
15 October - 2026
Atrandi Biosciences is at the American Society of Human Genetics (ASHG) 2026 Annual Meeting in Montreal, October 20–24. You'll find us at booth #319 throughout the meeting, and Rapolas Žilionis, PhD, co-founder and Chief Scientific Officer, is presenting twice on Wednesday, October 21.
Where to find us
| Industry Education Session | |
| Title | One Cell, Two Layers: Semi-Permeable Capsules as an Architecture for Scalable Single-Cell RNA and DNA Co-Sequencing |
| When | Wednesday, October 21, 1:00–1:30 pm ET |
| Where | CoLab Theater 1, Exhibit & Poster Hall |
| Scientific Poster | Title | Single-cell Multi-modal Profiling of Transcriptome and Genotype Reveals Clonal Dynamics in Acute Myeloid Leukemia |
| When | Wednesday, October 21, 2:30–4:30 pm ET |
| Where | Board 8176W |
What the sessions cover
Single-cell genomics is shaped by the compartment the chemistry happens in. A droplet is a closed reactor, reagents can be added, but nothing can be removed. Sequential reactions that need different conditions, such as cell lysis followed by amplification, therefore can't run on the same cell, which is why most single-cell assays read one molecular layer.
Semi-Permeable Capsules (SPCs) are built differently. An SPC is a droplet-like microcompartment, that has an aqueous core enclosed by a thin, semi-permeable hydrogel shell. Cells, genomic DNA, and other long nucleic acids stay inside, while enzymes, primers, and buffers diffuse freely in-and-out. A reaction is started, stopped, or exchanged by moving the capsules into a different buffer, with a pipette and a benchtop centrifuge. Multi-step workflows therefore run on tens of thousands of cells in parallel, each step under its own, optimal conditions.
RNA and DNA co-sequencing is the application built on these features. From the same cell, the assay reads a whole-transcriptome profile alongside targeted genotyping by multiplex PCR amplicon sequencing. Because the amplicons are raised from genomic DNA, they report the loci you choose regardless of expression, including loci that are not transcribed. Panels are user-defined, so they can combine recurrent disease-associated mutations with variants specific to an individual sample.
The industry session covers the architecture and what it means for assay design. The poster presents the assay applied to bone marrow in acute myeloid leukemia.
Come and talk to us
Come to booth #319 and meet our colleagues: Stephanie Gao, PhD, Field Application Scientist, Lee Lieberman and Kristof O'Connor, Commercial Development Executives. They are eager to get to know you throughout the meeting. If you're working on genotype–phenotype questions in primary tissue, CRISPR screen validation, or anything where knowing which cells carry which variants matters, that's the conversation we'd like to have.